[6-K] Enlivex Therapeutics Ltd. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Enlivex Therapeutics Ltd. filed a Form 6-K to report its Annual General Meeting of Shareholders is scheduled for November 10, 2025 at 7:00 p.m. Israel time at the company's offices, 14 Einstein Street, Nes Ziona, Israel. The report states that the meeting notice, proxy statement and a form of proxy card are attached as Exhibit 99.1 and Exhibit 99.2 and are incorporated by reference into the report. The filing is signed by CEO Oren Hershkovitz.

Positive

• Annual General Meeting scheduled for shareholders on November 10, 2025, providing clear logistics for participation
• Proxy materials attached as Exhibit 99.1 and Exhibit 99.2, enabling shareholders to review and vote

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine annual meeting notice with proxy materials attached; no substantive governance changes disclosed.

The filing provides a standard notification of the company's Annual General Meeting and attaches the meeting notice, proxy statement and proxy card as exhibits. There is no disclosure in this Form 6-K of proposed board changes, shareholder proposals, executive appointments or voting items themselves; those details would appear in the attached proxy statement. From a governance perspective this is a routine procedural filing that informs shareholders of logistics and provides the formal proxy materials for voting.

Securities Analyst

TL;DR: Administrative disclosure of meeting date and proxy materials; no financial or operational impacts reported.

The report confirms the date, time and location of the Annual General Meeting and states that the notice and proxy materials are attached as exhibits. The Form 6-K does not include financial results, material transactions or forward-looking information. For investors, the filing signals that voting materials are available, but does not present new information that would affect valuation or near-term financial analysis.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

_______________

Form 6-K

_______________

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934

For the month of: September 2025

Commission file number: 001-36578

_______________

ENLIVEX THERAPEUTICS LTD.

(Translation of registrant’s name into English)

_______________

14 Einstein Street, Nes Ziona, Israel 7403618

(Address of principal executive offices)

_______________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒            Form 40-F ☐

Annual General Meeting of Shareholders

On September 25, 2025, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), announced that it will hold its Annual General Meeting of Shareholders of the Company (the “Annual Meeting”) on Monday, November 10, 2025, beginning at 7:00 p.m. Israel time, at the offices of the Company located at 14 Einstein Street, Nes Ziona, Israel 7403618. Copies of the notice and proxy statement and the related proxy card are attached to this Report on Form 6-K as Exhibit 99.1 and Exhibit 99.2, respectively, and incorporated herein by reference.

Exhibit No.
99.1		Enlivex Therapeutics Ltd. Notice and Proxy Statement for the Annual General Meeting of Shareholders to be held on November 10, 2025.
99.2		Form of Proxy Card.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Enlivex Therapeutics Ltd.
		(Registrant)
		By:		/s/ Oren Hershkovitz
		Name:		Oren Hershkovitz
		Title:		Chief Executive Officer

Date: September 25, 2025

2

FAQ

When is Enlivex (ENLV) holding its 2025 Annual General Meeting?

The meeting is scheduled for November 10, 2025 at 7:00 p.m. Israel time.

Where will Enlivex's 2025 Annual General Meeting be held?

The meeting will be held at the company offices: 14 Einstein Street, Nes Ziona, Israel.

Are the proxy materials for Enlivex's meeting available?

Yes. The notice and proxy statement are attached to the Form 6-K as Exhibit 99.1 and the form of proxy card as Exhibit 99.2.

Who signed the Form 6-K for Enlivex?

The Form 6-K is signed by Oren Hershkovitz, Chief Executive Officer.

Does the Form 6-K disclose any board changes or material transactions?

No. The filing only announces the meeting date, location and attached proxy materials; it does not disclose board changes or material transactions.